← SynDRA
ATOMOXETINE
SynDRA canonical compound SYN0001288 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | SLC6A4 |
| Mechanism of action | Norepinephrine transporter inhibitor |
| Indication | attention-deficit/hyperactivity disorder (ADHD) |
| Disease area | neurology/psychiatry |
All known targets
- SLC6A2
- SLC6A4
- SLC6A3
- CYP2D6
- GRIN1
- Slc6a3
- Slc6a2
- NET
- KLF10
- KCNJ6
- KCNJ5
- KCNJ3
Mechanisms of action (all sources)
- Norepinephrine transporter inhibitor
- SLC6A2 INHIBITOR
Drug classes
- Norepinephrine Uptake Inhibitors
- Adrenergic Agents
- Adrenergic Uptake Inhibitors
- Membrane Transport Modulators
- Neurotransmitter Agents
- Neurotransmitter Uptake Inhibitors
- Norepinephrine Reuptake Inhibitor
ATC classes
- N06B · PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Cross-references
Synonyms
- LY139603
- strattera
- tomoxetine
- (-)-Tomoxetine
- atomoxetine hydrochloride
- tomoxetine hydrochloride
- atomoxetine HCl
- tomoxetine HCl
- Atomoxetina
- Atomoxetine component of ad-109
- Atomoxetine component of ad-313
- Atomoxetine component of ad109
- Atomoxetine component of ad313
- Tomoxetina
- Tomoxetine
- Tomoxetinum
- Tomoxetina [Spanish]
- Tomoxetine [INN]
- Tomoxetinum [Latin]
- Atomoxetine (INN)
- Attentin (TN)
- Strattera (TN)
- Tomoxetin (TN)
- (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
- AD-313 COMPONENT ATOMOXETINE
- ASW034S0B8
- AD-109 COMPONENT ATOMOXETINE
- AD109 COMPONENT ATOMOXETINE
- AD313 COMPONENT ATOMOXETINE
- methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine
- CHEBI:127342
- Tomoxetinum (Latin)
- methyl((3R)-3-(2-methylphenoxy)-3-phenylpropyl)amine
- atomoxetinum
- RefChem:56721
- DTXCID7024297
- N06BA09
- Strattera
Reported adverse events
- Abdominal pain
- Dizziness
- Dry mouth
- Dysuria
- Fatigue
- Headache
- Insomnia
- Nausea
- Seizure
- Palpitations
- Weight decreased
- Constipation
Look up ATOMOXETINE in the interactive SynDRA portal →